Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Amgen Inc. (AMGN : NSDQ)
 
 • Company Description   
Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.

Number of Employees: 28,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $297.00 Daily Weekly Monthly
20 Day Moving Average: 2,580,357 shares
Shares Outstanding: 537.71 (millions)
Market Capitalization: $159,698.72 (millions)
Beta: 0.49
52 Week High: $346.85
52 Week Low: $253.30
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.22% -1.82%
12 Week 0.58% -12.81%
Year To Date 13.95% 7.66%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ONE AMGEN CENTER DRIVE
-
THOUSAND OAKS,CA 91320
USA		 ph: 805-447-1000
fax: 805-447-1010		 investor.relations@amgen.com http://www.amgen.com
 
 • General Corporate Information   
Officers
Robert A. Bradway - Chief Executive Officer; Chairman of the Board and
Peter H. Griffith - Executive Vice President and Chief Financial Offic
Matthew C. Busch - Vice President; Finance and Chief Accounting Offic
Wanda M. Austin - Director
Michael V. Drake - Director

Peer Information
Amgen Inc. (CORR.)
Amgen Inc. (RSPI)
Amgen Inc. (CGXP)
Amgen Inc. (BGEN)
Amgen Inc. (GTBP)
Amgen Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 031162100
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 537.71
Most Recent Split Date: 11.00 (2.00:1)
Beta: 0.49
Market Capitalization: $159,698.72 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 3.21%
Current Fiscal Quarter EPS Consensus Estimate: $5.38 Indicated Annual Dividend: $9.52
Current Fiscal Year EPS Consensus Estimate: $20.82 Payout Ratio: 0.46
Number of Estimates in the Fiscal Year Consensus: 15.00 Change In Payout Ratio: 0.01
Estmated Long-Term EPS Growth Rate: 5.31% Last Dividend Paid: 05/16/2025 - $2.38
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 14.26
Trailing 12 Months: 14.31
PEG Ratio: 2.69
Price Ratios
Price/Book: 25.73
Price/Cash Flow: 9.78
Price / Sales: 4.68
EPS Growth
vs. Year Ago Period: 23.74%
vs. Previous Quarter: -7.72%
Sales Growth
vs. Year Ago Period: 9.43%
vs. Previous Quarter: -10.31%
ROE
06/30/25 - -
03/31/25 - 176.11
12/31/24 - 176.32
ROA
06/30/25 - -
03/31/25 - 12.39
12/31/24 - 11.71
Current Ratio
06/30/25 - -
03/31/25 - 1.17
12/31/24 - 1.26
Quick Ratio
06/30/25 - -
03/31/25 - 0.88
12/31/24 - 0.95
Operating Margin
06/30/25 - -
03/31/25 - 32.95
12/31/24 - 32.12
Net Margin
06/30/25 - -
03/31/25 - 17.39
12/31/24 - 12.24
Pre-Tax Margin
06/30/25 - -
03/31/25 - 19.49
12/31/24 - 13.79
Book Value
06/30/25 - -
03/31/25 - 11.54
12/31/24 - 10.93
Inventory Turnover
06/30/25 - -
03/31/25 - 1.74
12/31/24 - 1.65
Debt-to-Equity
06/30/25 - -
03/31/25 - 8.70
12/31/24 - 9.62
Debt-to-Capital
06/30/25 - -
03/31/25 - 89.69
12/31/24 - 90.59
 

Powered by Zacks Investment Research ©